| abstract |
An antibody for use in the reduction of cancer stem cells expressing EMP2 in a patient who has cancer and who has been previously identified that comprises cancer stem cells expressing EMP2 and one or more markers selected from the group consisting of CD44, CD 133 ABCG2 and ALDH, wherein: a) the antibody comprises a heavy chain that has the amino acid sequence: MAQVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRD NSKNTLYLQMNSLRAEDTAVYSCARD sequence, the amino acid chain has the antibody chain: the amino acid sequence: MAQVQLVQSGGGLVQPGRSLRLSCAASGFSFSEYPMHWVRQAPGRGLESVAVISYDGEYQKYADSVKGRFTISRD DSKSTVYLQMNSLRPEDTAVYYCARTINNGMDVWGQGTTVT and a light chain having the amino acid sequence: ** ** Formula c) the antibody comprises a heavy chain having the amino acid sequence: MAQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMHWVR QAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRD NSKNTLYLQMNSLRAEDTAVYYCARTVGATGAFDIWGQGTMVTVSSS and a light chain having the amino acid sequence: ** ** Formula d) the antibody comprises a heavy chain having the amino acid sequence: MAQVQLVQSGGGLVQPGRSLRLSCAASGFSFSEYPMHWVRQAPGRGLESVAVISYDGEYQKYADSVKGRFTISRD DSKSTVYLQMNSLRPEDTAVYYCARTINNGMDVWGQGTTVT and a light chain having the amino acid sequence: ** Formula ** e) the antibody competes for EMP2 binding with an antibody encoding a), b), c) or d); f) the antibody shares 90% amino acid identity with the variable regions of the heavy and light chains of an antibody according to a), b), c) or d); or g) the antibody comprises CDR sequences identical to those of an antibody according to a), b), c) or d). |